Guidelines for the use of platelet transfusions

NHSBT and Radcliffe Department of Medicine, University of Oxford, Oxford, NHSBT and Department of Haematology, North Bristol NHS Trust, Bristol, NHSBT and Department of Haematology, Royal London Hospital, London, Department of Haematology, Royal Cornwall Hospital Trust, Cornwall, Department of Critical Care Medicine & Anaesthesia, City Hospitals Sunderland NHS Foundation Trust, Sunderland, Department of Haematology, Royal Devon & Exeter NHS Foundation Trust, Exeter, School of Cellular and Molecular Medicine, University of Bristol, Bristol, NHSBT and Department of Haematology, John Radcliffe Hospital, Oxford and NHSBT, Newcastle upon Tyne, UK

[1]  N. Goulden,et al.  The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation , 2002, British journal of haematology.

[2]  K. Ahrar,et al.  Transjugular liver biopsy in patients with hematologic malignancy and severe thrombocytopenia. , 2003, Journal of vascular and interventional radiology : JVIR.

[3]  V. Kiefel,et al.  Platelet alloantibodies in transfused patients , 2001, Transfusion.

[4]  M. Napolitano,et al.  Ultrasonography-guided central venous catheterisation in haematological patients with severe thrombocytopenia. , 2013, Blood transfusion = Trasfusione del sangue.

[5]  V. Novotny.  Prevention and Management of Platelet Transfusion Refractoriness , 1999, Vox Sanguinis.

[6]  L. Adès.  Guidelines for the Diagnosis and Management of , 2006 .

[7]  Paul Harrison,et al.  The accuracy of platelet counting in thrombocytopenic blood samples distributed by the UK National External Quality Assessment Scheme for General Haematology. , 2012, American journal of clinical pathology.

[8]  G. Escolar,et al.  Recombinant human erythropoietin treatment improves platelet function in uremic patients. , 1992, Kidney international.

[9]  A. Tobian,et al.  The cost‐effectiveness of platelet additive solution to prevent allergic transfusion reactions , 2013, Transfusion.

[10]  M. Trivella,et al.  Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. , 2014, The Cochrane database of systematic reviews.

[11]  J. George,et al.  The clinical importance of acquired abnormalities of platelet function. , 1991, The New England journal of medicine.

[12]  William M. Lee,et al.  Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  P. Rebulla,et al.  The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. , 2006, Haematologica.

[14]  G. Delage,et al.  The role of leukodepletion in the control of transfusion-transmitted disease. , 1995, Transfusion medicine reviews.

[15]  V. Fuster,et al.  Normalization of platelet reactivity in clopidogrel‐treated subjects , 2007, Journal of thrombosis and haemostasis : JTH.

[16]  J. Byrnes,et al.  Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. , 1981, JAMA.

[17]  M. Trivella,et al.  Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. , 2013, The Cochrane database of systematic reviews.

[18]  J. Vose,et al.  A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. , 1998, Blood.

[19]  H. Lazarus,et al.  Lowering the Prophylactic Platelet Transfusion Threshold: a Prospective Analysis , 2001, Leukemia & lymphoma.

[20]  A. Sauaia,et al.  Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. , 2012, Journal of the American College of Surgeons.

[21]  P. Rebulla,et al.  Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. , 2015, Transfusion medicine reviews.

[22]  M. Shuman,et al.  Management of treatment failures in thrombotic thrombocytopenic purpura , 1986, American journal of hematology.

[23]  M. Murphy,et al.  National comparative audit of the use of platelet transfusions in the UK. , 2007, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[24]  N. Fisher,et al.  Central venous cannulation in patients with liver disease and coagulopathy – a prospective audit , 1999, Intensive Care Medicine.

[25]  H. Greinix,et al.  Platelet‐reactive HLA antibodies associated with low posttransfusion platelet increments:a comparison between the monoclonal antibody‐specific immobilization of platelet antigens assay and the lymphocytotoxicity test , 2001, Transfusion.

[26]  R. Pasquini,et al.  Intracranial hemorrhage following bone marrow transplantation: an autopsy study of 58 patients , 2002, Bone Marrow Transplantation.

[27]  C. Mueller-Eckhardt,et al.  High‐dose intravenous immunoglobulin for post‐transfusion purpura , 1985, The New England journal of medicine.

[28]  P. Wouters,et al.  Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. , 2013, European journal of anaesthesiology.

[29]  M. Regueiro,et al.  Management of persistent gastric bleeding in a patient with Glanzmann's thrombasthenia , 2008, American journal of hematology.

[30]  H. Masuzaki,et al.  Real-time ultrasound-guided central venous catheterization reduces the need for prophylactic platelet transfusion in thrombocytopenic patients with hematological malignancy. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[31]  J. Cazenave,et al.  Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3‐year period , 2011, Transfusion.

[32]  J. Byrnes.  Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura , 1981, Seminars in thrombosis and hemostasis.

[33]  G. Wang,et al.  Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. , 2013, JAMA surgery.

[34]  A. Brand.  Alloimmune platelet refractoriness:incidence declines, unsolved problems persist , 2001, Transfusion.

[35]  R. Barrera,et al.  Acute complications of central line placement in profoundly thrombocytopenic cancer patients , 1996, Cancer.

[36]  Marco Cattaneo,et al.  Desmopressin (DDAVP) , 2019, Platelets.

[37]  J. Grande,et al.  Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. , 2005, The American journal of medicine.

[38]  S. Hopewell,et al.  Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. , 2012, The Cochrane database of systematic reviews.

[39]  C. Hillyer,et al.  Methods for the reduction of transfusion‐transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units , 1994, Transfusion.

[40]  M. Trivella,et al.  Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. , 2014, The Cochrane database of systematic reviews.

[41]  S. Archan,et al.  Low platelet reactivity is recovered by transfusion of stored platelets: a healthy volunteer in vivo study , 2011, Journal of thrombosis and haemostasis : JTH.

[42]  E. Freireich.  Supportive care for patients with blood disorders. , 2000, British journal of haematology.

[43]  E. Wood,et al.  A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. , 2015, The Cochrane database of systematic reviews.

[44]  A. Laupacis,et al.  Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement , 2001, Transfusion.

[45]  Inderjeet Dokal,et al.  Guidelines for the diagnosis and management of adult aplastic anaemia , 2016, British journal of haematology.

[46]  M. Trivella,et al.  Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. , 2014, The Cochrane database of systematic reviews.

[47]  Maniruzzaman,et al.  Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial , 2013 .

[48]  T. Simon,et al.  Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. , 1984, The Annals of thoracic surgery.

[49]  T. Pysher,et al.  Testing platelet mass versus platelet count to guide platelet transfusions in the neonatal intensive care unit , 2009, Transfusion.

[50]  Williamson,et al.  Prevention of transfusion‐transmitted cytomegalovirus infection , 1999, Transfusion medicine.

[51]  P. Vyas,et al.  Guidelines for the diagnosis and management of adult myelodysplastic syndromes , 2014, British journal of haematology.

[52]  R. B. Babcock,et al.  Heparin-induced immune thrombocytopenia. , 1976, The New England journal of medicine.

[53]  T. Lister,et al.  Relative Importance of Immune and Non‐Immune Causes of Platelet Refractoriness , 1994, Vox sanguinis.

[54]  M. Trivella,et al.  Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. , 2015, The Cochrane database of systematic reviews.

[55]  R. Hawker,et al.  Paired in vivo and in vitro comparison of apheresis and “recovered” platelet concentrates stored for 5 days , 1994, Journal of clinical apheresis.

[56]  L. Estcourt.  Why has demand for platelet components increased? A review , 2014, Transfusion medicine.

[57]  A. Mackley,et al.  Transfusing neonates based on platelet count vs. platelet mass: A randomized feasibility-pilot study , 2014, Platelets.

[58]  G. Rodgers,et al.  Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia , 2000, American journal of hematology.

[59]  American Association for the Study of Liver Diseases Postgraduate courses and 48th annual meeting. Chicago, Illinois, November 7-11, 1997. Abstracts. , 1997, Hepatology.

[60]  A. Dans,et al.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[61]  P. Mannoni,et al.  [Platelet transfusion]. , 1976, Revue francaise de transfusion et immuno-hematologie.

[62]  Frank Saran,et al.  Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force , 2011, British journal of haematology.

[63]  P. Cluzel,et al.  Transjugular versus percutaneous renal biopsy for the diagnosis of parenchymal disease: comparison of sampling effectiveness and complications. , 2000, Radiology.

[64]  K. Ohashi,et al.  Intracranial hemorrhage following allogeneic hematopoietic stem cell transplantation , 2009, American journal of hematology.

[65]  C. Fisher,et al.  Morbidity and Mortality in Adults With “Idiopathic” Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome , 1994 .

[66]  M. Greaves,et al.  Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Maternal and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task Force of the British Society for Haematology. , 1996, British journal of haematology.

[67]  A. Andriulli,et al.  Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. , 2012, The New England journal of medicine.

[68]  R. Prescott,et al.  Thrombocytopenia and platelet transfusion in UK critical care: a multicenter observational study , 2013, Transfusion.

[69]  C. Samama,et al.  Perioperative platelet transfusion. Recommendations of the French Health Products Safety Agency (AFSSAPS) 2003. , 2006, Minerva anestesiologica.

[70]  D Stainsby,et al.  Management of massive blood loss: a template guideline. , 2000, British journal of anaesthesia.

[71]  R. Aster,et al.  Thrombotic thrombocytopenic purpura: Early and late responders , 1997, American journal of hematology.

[72]  S. Kleinman,et al.  Platelet transfusion: a systematic review of the clinical evidence , 2015, Transfusion.

[73]  S. Lewis,et al.  British Committee for Standards in Haematology , 1969 .

[74]  J. Holland,et al.  The Prophylactic Treatment of Thrombocytopenic Leukemic Patients with Platelets: a Double Blind Study , 1974, Transfusion.

[75]  S. Stanworth,et al.  Platelet transfusions for critically ill patients with thrombocytopenia. , 2014, Blood.

[76]  P. Rebulla,et al.  A comparative analysis of different methods for routine blood component preparation. , 1997, Transfusion medicine reviews.

[77]  W. Wiktor-Jedrzejczak,et al.  Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study , 2012 .

[78]  Matthew S. Johnson,et al.  Time to hemostasis after traction removal of tunneled cuffed central venous catheters. , 2007, Journal of vascular and interventional radiology : JVIR.

[79]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[80]  C. Mueller-Eckhardt,et al.  High-dose IgG treatment for neonatal alloimmune thrombocytopenia , 1989, Blut.

[81]  G. Schoch,et al.  A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. , 1995, Blood.

[82]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[83]  P. Rebulla,et al.  Efficacy of HLA‐matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review , 2013, Transfusion.

[84]  A. Velardi,et al.  The EBMT activity survey: 1990–2010 , 2012, Bone Marrow Transplantation.

[85]  R. Strauss,et al.  Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  T. Hervig,et al.  Low frequency of anti‐D alloimmunization following D+ platelet transfusion: the Anti‐D Alloimmunization after D‐incompatible Platelet Transfusions (ADAPT) study , 2015, British journal of haematology.

[87]  W. Tsay,et al.  Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  R. Aster,et al.  Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. , 1986, Annals of internal medicine.

[89]  A. McDonald,et al.  Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial , 2010, The Lancet.

[90]  G. Ehninger,et al.  Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. , 1998, Blood.

[91]  W. Whittier,et al.  Timing of complications in percutaneous renal biopsy. , 2004, Journal of the American Society of Nephrology : JASN.

[92]  L. Estcourt,et al.  Platelet transfusions for patients with haematological malignancies: who needs them? , 2011, British journal of haematology.

[93]  E. Wood,et al.  Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial (CME) , 2014, Transfusion.

[94]  C. Francis,et al.  ABO‐immune complex formation and impact on platelet function, red cell structural integrity and haemostasis: an in vitro model of ABO non‐identical transfusion , 2016, Vox sanguinis.

[95]  L. Gesualdo,et al.  Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. , 2004, Kidney international.

[96]  S. Stanworth,et al.  A practical guideline for the haematological management of major haemorrhage , 2015, British journal of haematology.

[97]  N. Jaffe,et al.  Prophylactic Platelet Transfusions in Children with Acute Leukemia: A Dose Response Study , 1973, Transfusion.

[98]  A. Greinacher,et al.  Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study , 2012, Journal of thrombosis and haemostasis : JTH.

[99]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[100]  Acute bleeding after bone marrow transplantation (BMT)- incidence and effect on survival. A quantitative analysis in 1,402 patients , 1998 .

[101]  L. Oğuzkurt,et al.  US-guided placement of central vein catheters in patients with disorders of hemostasis. , 2008, European journal of radiology.

[102]  J. Bromberg,et al.  An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival , 2013, BMC Nephrology.

[103]  Rustam Al-Shahi Salman,et al.  Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial , 2016, The Lancet.

[104]  E. Taft.  Thrombotic thrombocytopenic purpura and dose of plasma exchange. , 1979, Blood.

[105]  M. Mazumdar,et al.  Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety , 2014, BMJ : British Medical Journal.

[106]  P. Rebulla,et al.  Prophylactic platelet transfusions , 2012, Vox sanguinis.

[107]  J. Fehr,et al.  Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia , 1991, The Lancet.

[108]  J. Vincent,et al.  Management of bleeding following major trauma: an updated European guideline , 2010, Critical care.

[109]  X. Thomas,et al.  Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients , 2013, Cancer.

[110]  F. Roudot-thoraval,et al.  The temporary use of thrombopoietin‐receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study , 2014, British journal of haematology.

[111]  P. Rebulla,et al.  Utility of cross‐matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review , 2014, Transfusion.

[112]  L. Estcourt,et al.  Platelet transfusions in haematology patients: are we using them appropriately? , 2012, Vox sanguinis.

[113]  J. M. Carr,et al.  Efficacy of platelet transfusions in immune thrombocytopenia. , 1986, The American journal of medicine.

[114]  G. Rodgers,et al.  Treatment of immune‐mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: A retrospective review of 40 patients , 2008, American journal of hematology.

[115]  J. Encke,et al.  Low Levels of Prothrombin Time (INR) and Platelets Do Not Increase the Risk of Significant Bleeding when Placing Central Venous Catheters* , 2009, Medizinische Klinik.

[116]  B. Bain.  Bone marrow biopsy morbidity and mortality , 2003, British journal of haematology.

[117]  N. Dunbar,et al.  Easier said than done: ABO compatibility and D matching in apheresis platelet transfusions , 2015, Transfusion.

[118]  C. Milkins,et al.  Guidelines for pre‐transfusion compatibility procedures in blood transfusion laboratories , 2013, Transfusion medicine.

[119]  L. Cavanna,et al.  Ultrasound-guided central venous catheterization in cancer patients improves the success rate of cannulation and reduces mechanical complications: A prospective observational study of 1,978 consecutive catheterizations , 2010, World journal of surgical oncology.

[120]  A G Randolph,et al.  Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature. , 1996, Critical care medicine.

[121]  Je-Hwan Lee,et al.  Analysis of fatal intracranial hemorrhage in 792 acute leukemia patients. , 2004, Haematologica.

[122]  G. Remuzzi,et al.  Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. , 1983, The New England journal of medicine.

[123]  J. Sixma,et al.  Treatment of Uremic Anemia with Recombinant Erythropoietin also Reduces the Defects in Platelet Adhesion and Aggregation Caused by Uremic Plasma , 1991, Thrombosis and Haemostasis.

[124]  B. Sibai,et al.  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in pregnancy: review of 11 cases. , 1996, American journal of obstetrics and gynecology.

[125]  C. Manno,et al.  Does red‐cell T activation matter? , 2001, British journal of haematology.

[126]  M. Cattaneo,et al.  Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[127]  M. Hart,et al.  Central venous catheterization in patients with coagulopathy. , 1992, Archives of surgery.

[128]  S. Zehtabchi,et al.  Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: A systematic review , 2012, The journal of trauma and acute care surgery.

[129]  E. Cholongitas,et al.  Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review. , 2007, Journal of hepatology.

[130]  E. Massey,et al.  Guideline on the investigation and management of acute transfusion reactions Prepared by the BCSH Blood Transfusion Task Force , 2012, British journal of haematology.

[131]  A. Eldor,et al.  High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. , 1987, The American journal of medicine.

[132]  A. Grant,et al.  Guidelines on the use of liver biopsy in clinical practice , 1999, Gut.

[133]  Junzhe Chen,et al.  Factors that can minimize bleeding complications after renal biopsy , 2014, International Urology and Nephrology.

[134]  W. Wiktor-Jedrzejczak,et al.  Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia , 2014, Cancer.

[135]  S. Vesely,et al.  Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura , 2009, Transfusion.

[136]  Yanhong Wang,et al.  Tranexamic Acid in on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation: randomized trial and 1-year follow-up. , 2013, The Annals of thoracic surgery.

[137]  J. Esteve,et al.  Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. , 2008, Blood.

[138]  E. Wood,et al.  A no-prophylaxis platelet-transfusion strategy for hematologic cancers. , 2013, The New England journal of medicine.

[139]  B. Hunt,et al.  Indications for therapeutic platelet transfusions. , 1998, Blood reviews.

[140]  D. Goldfinger,et al.  Platelet transfusions in heparin‐induced thrombocytopenia: a report of four cases and review of the literature , 2008, Transfusion.

[141]  T. Barbui,et al.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1997, The New England journal of medicine.

[142]  J. Mira,et al.  Causes and risk factors of death in patients with thrombotic microangiopathies , 2012, Intensive Care Medicine.

[143]  L. Estcourt,et al.  Prophylactic platelet transfusions , 2010, Current opinion in hematology.

[144]  J. Vincent,et al.  Management of bleeding and coagulopathy following major trauma: an updated European guideline , 2013, Critical Care.

[145]  S. Trerotola,et al.  Large-bore tunneled central venous catheter insertion in patients with coagulopathy. , 2010, Journal of vascular and interventional radiology : JVIR.

[146]  Norfolk,et al.  CONSENSUS CONFERENCE ON PLATELET TRANSFUSION, ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 27–28 NOVEMBER 1997: Synopsis of background papers , 1998, British journal of haematology.

[147]  J. Stockman.  Inflammation induces hemorrhage in thrombocytopenia , 2010 .

[148]  J. Segal,et al.  The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. , 2008, Blood.

[149]  J. Akram,et al.  Effectiveness of Platelet Transfusion in Dengue Fever: A Randomized Controlled Trial , 2013, Transfusion Medicine and Hemotherapy.

[150]  J. Darin,et al.  Thrombotic Thrombocytopenic Purpura: Experience with Whole Blood Exchange Transfusion , 1981, Seminars in thrombosis and hemostasis.

[151]  A. Ho,et al.  Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study , 2012, The Lancet.

[152]  K. Yuen,et al.  Clinical factors influencing the efficacy of pooled platelet transfusions , 1988 .

[153]  D. Signorelli.  Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia , 2013 .

[154]  J M Rainey,et al.  Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  E. Ambinder,et al.  In Vitro and in Vivo Comparison of Single‐Donor Platelets and Multiple‐Donor Pooled Platelets Transfusions in Leukemic Patients , 1978, Transfusion.

[156]  F. Peyvandi,et al.  Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies , 2012, British journal of haematology.

[157]  M. Slim,et al.  The safety of central line placement prior to treatment of pediatric acute lymphoblastic leukemia , 2006, Pediatric Blood & Cancer.

[158]  G. Escolar,et al.  Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: Association with early improvement in platelet function , 1998, American journal of hematology.

[159]  J. Shim,et al.  Effect of tranexamic acid on transfusion requirement in dual antiplatelet-treated anemic patients undergoing off-pump coronary artery bypass graft surgery. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[160]  B. Pollock,et al.  A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[161]  J. George,et al.  Glanzmann's thrombasthenia: the spectrum of clinical disease. , 1990, Blood.

[162]  P. Mannucci.  Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. , 1997, Blood.

[163]  M. Laffan,et al.  Guideline on the management of bleeding in patients on antithrombotic agents , 2013, British journal of haematology.

[164]  W. Hiddemann,et al.  Frequency and causes of refractoriness in multiply transfused patients , 1997, Annals of Hematology.

[165]  A. Jayarajan,et al.  Post-transfusion purpura. , 2002, The Journal of the Association of Physicians of India.

[166]  Edward J. Lee,et al.  The value of 10‐minute posttransfusion platelet counts , 1988, Transfusion.

[167]  J. Wetterslev,et al.  Fibrinogen concentrate in bleeding patients. , 2013, The Cochrane database of systematic reviews.

[168]  T. Nokes,et al.  The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals , 2010, British journal of haematology.

[169]  H. Lehmann,et al.  Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. , 2002, Transfusion medicine reviews.

[170]  H. Watson,et al.  Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second edition , 2012, British journal of haematology.

[171]  J. Moake,et al.  Heparin‐induced thrombocytopenia: Association with a platelet aggregating factor and arterial thromboses , 1979, American journal of hematology.

[172]  S. Watson,et al.  A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO , 2006, British journal of haematology.

[173]  J. le Gall,et al.  High-Dose Plasma Infusion versus Plasma Exchange as Early Treatment of Thrombotic Thrombocytopenic Purpura/Hemolytic-Uremic Syndrome , 2003, Medicine.

[174]  M. Sagmeister,et al.  A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. , 1999, Blood.

[175]  O. Senn,et al.  Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia , 2011, Transfusion.

[176]  H. Ohto,et al.  Non‐D Rh antibodies appearing after apheresis platelet transfusion: stimulation by red cells or microparticles? , 2011, Vox sanguinis.

[177]  Benjamin Djulbegovic,et al.  Platelet Transfusion: A Clinical Practice Guideline From the AABB , 2015, Annals of Internal Medicine.

[178]  R. Larson,et al.  A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide , 2012, Journal of Hematology & Oncology.

[179]  B. Bain,et al.  Bone marrow biopsy morbidity: review of 2003 , 2005, Journal of Clinical Pathology.

[180]  B. Shaz,et al.  A comparison of adverse reaction rates for PAS C versus plasma platelet units , 2014, Transfusion.

[181]  Shawn C. Nessen,et al.  Risks of hemolysis due to anti‐A and anti‐B caused by the transfusion of blood or blood components containing ABO‐incompatible plasma , 2013, Transfusion.

[182]  W. Sibrowski,et al.  2 Platelet Concentrates , 2009, Transfusion Medicine and Hemotherapy.

[183]  J. Wood,et al.  Guidelines on hospital blood bank documentation and procedures. British Committee for Standards in Haematology, Blood Transfusion Task Force. , 1990, Clinical and laboratory haematology.

[184]  G. Rock,et al.  Evaluation of platelet transfusion triggers in a tertiary‐care hospital , 2007, Transfusion.

[185]  P. Greenberg,et al.  A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine , 2013, Leukemia & lymphoma.

[186]  P. Moncharmont,et al.  Red blood cell alloimmunisation after platelet transfusion: a 5-year study. , 2014, Blood transfusion = Trasfusione del sangue.

[187]  W. Ouwehand,et al.  Provision of platelets for severe neonatal alloimmune thrombocytopenia. , 1997, British journal of haematology.

[188]  A. Godier,et al.  Inefficacy of platelet transfusion to reverse ticagrelor. , 2015, The New England journal of medicine.

[189]  J. McCullough,et al.  Platelet utilization and the transfusion trigger: a prospective analysis , 2007, Transfusion.

[190]  I. Rutkow.  Thrombotic Thrombocytopenic Purpura (TTP) and Splenectomy: A Current Appraisal , 1978, Annals of surgery.

[191]  A. Busti,et al.  Evidence-based treatment recommendations for uremic bleeding , 2007, Nature Clinical Practice Nephrology.

[192]  S. Slichter.  Controversies in platelet transfusion therapy. , 1980, Annual review of medicine.

[193]  J. Menitove.  Immunoprophylaxis for D− patients receiving platelet transfusions from D−donors? , 2002 .

[194]  C. Martínez,et al.  Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. , 1996, Bone marrow transplantation.

[195]  A. Loh,et al.  Port-A-Cath insertions in acute leukemia: does thrombocytopenia affect morbidity? , 2007, Journal of pediatric surgery.

[196]  Steven M. Duffy,et al.  Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura , 2011, Journal of clinical apheresis.

[197]  S. Hiippala.  Replacement of Massive Blood Loss , 1998, Vox sanguinis.

[198]  T. Warkentin.  How I diagnose and manage HIT. , 2011, Hematology. American Society of Hematology. Education Program.

[199]  S. Stanworth,et al.  Guidelines on transfusion for fetuses, neonates and older children , 2016, British journal of haematology.

[200]  A. Shamseddine,et al.  Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center , 2004, Journal of clinical apheresis.

[201]  B. Hunt,et al.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias , 2003, British journal of haematology.

[202]  A. Grayson,et al.  A meta-analysis to determine the effect on survival of platelet transfusions in patients with either spontaneous or traumatic antiplatelet medication-associated intracranial haemorrhage , 2012, BMJ Open.

[203]  Daniel Hind,et al.  Ultrasonic locating devices for central venous cannulation: meta-analysis , 2003, BMJ : British Medical Journal.

[204]  G. Liumbruno,et al.  Recommendations for the transfusion of plasma and platelets. , 2009, Blood transfusion = Trasfusione del sangue.

[205]  A. Tobian,et al.  The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME) , 2014, Transfusion.

[206]  M. Menegus,et al.  Outcomes after platelet transfusion in patients with heparin‐induced thrombocytopenia , 2010, Journal of thrombosis and haemostasis : JTH.

[207]  G. Liumbruno,et al.  Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period. , 2011, Blood transfusion = Trasfusione del sangue.

[208]  F. Orsi,et al.  Coagulation disorders in patients with cancer: nontunneled central venous catheter placement with US guidance--a single-institution retrospective analysis. , 2009, Radiology.

[209]  C. Hesse,et al.  Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. , 2014, British journal of anaesthesia.

[210]  K. Koike,et al.  Replaced platelet concentrates containing a new additive solution, M‐sol: safety and efficacy for pediatric patients , 2013, Transfusion.

[211]  L. Goodnough,et al.  Reducing the Risk for Transfusion-transmitted Cytomegalovirus Infection , 1992, Annals of Internal Medicine.

[212]  F. Schena,et al.  Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[213]  E. Massey,et al.  BCSH guideline for the use of anti‐D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn , 2014, Transfusion medicine.

[214]  Paul J. Harrison,et al.  Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion , 2005, British journal of haematology.

[215]  J. Hirsh,et al.  REVERSAL OF THE ANTI-PLATELET EFFECTS OF ASPIRIN AND CLOPIDOGREL , 2012, Heart.

[216]  B. Bain.  Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. , 2006, Haematologica.

[217]  B. Bain.  Bone marrow biopsy morbidity and mortality: 2002 data. , 2004, Clinical and laboratory haematology.

[218]  G. Vogelsang,et al.  Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 × 109 and 20 × 109 per L , 2007, Transfusion.

[219]  A. Eldor,et al.  Prediction of haemorrhagic diathesis in thrombocytopenia by mean platelet volume. , 1982, British medical journal.

[220]  C. Ray,et al.  Patients with thrombocytopenia: outcome of radiologic placement of central venous access devices. , 1997, Radiology.

[221]  Rachel J. Johnson,et al.  Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis , 2015, Haematologica.

[222]  L. Raghuram,et al.  Transjugular liver biopsy: a retrospective analysis of 601 cases. , 2008, Journal of vascular and interventional radiology : JVIR.

[223]  P. Terasaki,et al.  Suppression of transfusion-related alloimmunization in intensively treated cancer patients. , 1981, Blood.

[224]  L. Gordon,et al.  Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. , 1987, Seminars in hematology.

[225]  F. Grumet,et al.  Platelet transfusion therapy; the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. , 1969, The New England journal of medicine.

[226]  N. Blumberg,et al.  ABO matching of platelet transfusions - "Start Making Sense". "As we get older, and stop making sense…" - The Talking Heads (1984). , 2015, Blood transfusion = Trasfusione del sangue.

[227]  J. Wallis,et al.  Where did platelets go in 2012? A survey of platelet transfusion practice in the North of England , 2014, Transfusion medicine.

[228]  Phil Edwards,et al.  Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis , 2012, BMJ : British Medical Journal.

[229]  D. Hart,et al.  Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation , 2006, Transfusion medicine.

[230]  A. Reiner,et al.  RBC T activation and hemolysis: implications for pediatric transfusion management , 2000, Transfusion.

[231]  A. Alves,et al.  Postoperative bleeding after dental extraction in liver pretransplant patients. , 2012, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[232]  B. Chong,et al.  Heparin-induced Thrombocytopenia: Towards Consensus , 1998, Thrombosis and Haemostasis.

[233]  A. Chetrit,et al.  A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. , 1995, Leukemia & lymphoma.

[234]  M. Doerfler,et al.  Central venous catheter placement in patients with disorders of hemostasis. , 1996, Chest.

[235]  P J Horsey,et al.  Multiple trauma and massive transfusion , 1997, Anaesthesia.

[236]  M. Lahutte,et al.  Peripherally inserted central catheter placement in cancer patients with profound thrombocytopaenia: a prospective analysis , 2013, European Radiology.

[237]  H. Kiesewetter,et al.  Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia , 2008, Thrombosis and Haemostasis.

[238]  R. Correa-Rotter,et al.  Percutaneous renal biopsy of native kidneys: efficiency, safety and risk factors associated with major complications , 2011, Archives of medical science : AMS.

[239]  Yow-Ming C Wang,et al.  Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes , 2011, Cancer.